Happy this is the last trip we'll ever take with the declining @SouthwestAir Thx to mechanical incompetence I get to miss my Christmas birthday dinner. Crappy plane. No amenities. Late. No air. No lounges. Happy to pay more for a better travel experience in 2026 #seeya
@SouthwestAir not cool. I paid the highest ticket price and had A2 boarding. Got my favorite exit row seat and an oversized lady sits next to me. Not a lot of room even here! I don't think she's belted in. Can she really help in an emergency??? How is this allowed? Flight #3715
Biotech IPOs are the industry's lifeblood. They often IPO very early.
because it takes a lot of money, a lot of time, if ever, to get an asset FDA approved. Years ago the stat I had was ~5 in 5000 compounds get FDA approval. And then, there's the commercialization of an approved compound. How many commercialization efforts fail?
It's ridiculous for retail investors to ask the C-Suite when they're going to have a product! Learn to trade pre-revenue stocks. Read the freaking pipeline! Just saying... #myexperience #idiots #stocks #trading
GeoVax's multi-antigen vaccine platform is making waves in the market, especially when compared to single-antigen vaccine developers. $GOVX $NVAX
https://t.co/X0Pb3YBniS
Roth has noted that GEO-CM04S1 is already outperforming mRNA COVID vaccines in a smaller Phase 2 trial right after RFK Jr. says they are prioritizing polyvalent vaccines against respiratory viruses. $GOVX
https://t.co/fIxReFDvtS
GeoVax is a company to watch in the biotechnology industry. Their innovative approach to vaccine development is making a real impact. #COVID19#vaccine#biotechnology https://t.co/gsQ8CdHR2F
We want to welcome @Geovax_News to the @ROTHCapital Partners 3rd Annual Healthcare Opportunities Conference October 9th. See their profile on @B2iDigital at https://t.co/5MsVsQ9rvX
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers using novel proprietary platforms. GeoVax’s product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and therapy for advanced head and neck cancer. Additional development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, and Marburg), malaria and Zika virus, as well as therapies for various solid tumors. (Source: Company Website 08.06.24)
We look forward to seeing the continued results from David A. Dodd, Arban Domi, Mary Hauser, Susan Hensley, MS, RAC, Kelly McKee, Mark Newman, John Niles, Tom O'Brien, Sreenivasa Rao Oruganti, J. Marc Pipas, MD, Erica Raiden, Mark Reynolds, John W. Sharkey, Jeff Welch, Ashley Zuniga, PhD PMP and the entire GeoVax Labs, Inc. team!
Thanks to the stellar team at ROTH for organizing this conference: Sagar Sheth, Byron Roth, Isabel Mattson-Pain, Amanda McAdams, Otilia "Charo" Montano, Benjamin Bowen, James Antonopoulos, Jason Wittes, Jonathan Aschoff, Ph.D., Boobalan Pachaiyappan, Ph.D. and many others
ROTH is a relationship-driven investment bank headquartered in Newport Beach, CA. For more information on ROTH, please visit https://t.co/f7LaejqxRB.
We hope you’ll be able to attend this pivotal event shaping the future of healthcare innovation.